Remove Document Remove Drug Development Remove Licensing
article thumbnail

Drug repurposing patent documents vs peer review: patent information comes more than 600 days earlier on average

Drug Patent Watch

This article was originally published by Hermann Mucke & Peter Mucke in Future Drug Discovery under a Attribution-NonCommercial-NoDerivatives 4.0 Unported License. link] Drug developers require access to scientific information in….

article thumbnail

Strengthening Warfighter Resiliency Using Broad-Spectrum or Host-Directed Therapies within the Rapid Acquisition and Investigation of Drugs for Repurposing (RAIDR) Program [Minireview]

ASPET

To maintain cadence with looming threats in a prolonged field care environment, the broader medical countermeasure (MCM) enterprise must adopt new strategies for CBRN-addressing drug development. Repurposing is one such method.

Therapies 100
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Using Rapid Development Environment in AEM as a Cloud Service

Perficient: Drug Development

Depending on the size of the team and anticipated activity within a program, additional RDEs can also be provisioned, however, this may come at an additional licensing cost from Adobe. Creating an Rapid Development Environment The RDE can be provisioned with a Program via Cloud Manager in AEM as a Cloud Service.

Packaging 105
article thumbnail

Testing Permission Sets in Salesforce

Perficient: Drug Development

Document the specific changes made to the permission set and assign it to a test user to check if the modifications are reflected correctly. Test with different license types : If the permission set is assigned to users with different license types, test it with each license type to ensure that the permissions work as expected.

article thumbnail

Analysis Life Sciences Thank You Unpacking FDA’s long-awaited platform technology designation program and guidance

Agency IQ

Unpacking FDA’s long-awaited platform technology designation program and guidance Months overdue, the FDA’s Platform Technologies Designation guidance document has just been published by the agency. AgencyIQ breaks down what the designation means for sponsors and its limits for product sponsors.

Science 40
article thumbnail

DFS500 Amendments: What You Need to Know

Perficient: Drug Development

Issues and Findings Management: Document issues and gaps identified during risk assessments and control testing, crucial for compliance. DFS500 Compliance Requirements Institutions falling under the purview of the DFS500 amendments encompass a diverse spectrum, all mandated to adhere to these regulations.

article thumbnail

Concurrent Validation for Breakthrough and Orphan Drugs: Meeting the Needs for Accelerated Manufacturing

The Premier Consulting Blog

This process can be initiated during the review period of the biologics license application (BLA) or new drug application (NDA) prior to approval. 490.100 titled, “Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval.”